Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Catumaxomab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Lindis Biotech
Deal Size : Undisclosed
Deal Type : Agreement
Celonic, LINDIS Biotech Sign Manufacturing Agreement for Catumaxomab
Details : Under the agreement, Celonic Group will leverage its expertise in GMP manufacturing to produce Removab (catumaxomab). It is being indicated for the treatment of malignant ascites in adult patients.
Product Name : Removab
Product Type : Antibody
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : Catumaxomab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Lindis Biotech
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : CureVac
Deal Size : Undisclosed
Deal Type : Agreement
Details : Celonic will be prepared to manufacture more than 100 million doses of CVnCoV. More than 50 million doses are expected to be produced before the end of 2021.
Product Name : CVnCoV
Product Type : Vaccine
Upfront Cash : Undisclosed
March 30, 2021
Lead Product(s) : CVnCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : CureVac
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Agreement
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
Details : Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Zelpultide Alpha
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Airway Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.
Product Name : AT-100
Product Type : Protein
Upfront Cash : Undisclosed
May 20, 2020
Lead Product(s) : Zelpultide Alpha
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Airway Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration